Potential molecular marker for detecting transitional cell carcinoma

Chiu, Allen W.; Huang, Yu; Huan, Steven K.; Wang, Yu Chun; Ju, Jyh Phen; Chen, Mei Fang; Chou, Chen Kung

doi:10.1016/s0090-4295(02)01672-2

Cited by 33 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, information on DLG7 in urological diseases and particularly in CaP is limited [34]. In one study, transcripts for DLG7 were detected in nearly 90 percent of transitional cell carcinoma (TCC) of the bladder, but not in benign urological diseases; a high level of transcripts for DLG7 was found in recurrent TCC [41]. …”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

et al. 2013

View full text Add to dashboard Cite

Hypoxia has been associated with malignant progression, metastasis and resistance to therapy. Hence, we studied expression of hypoxia–regulated genes in 100 prostate cancer (CaP) bulk tissues and 71 adjacent benign tissues. We found 24 transcripts significantly overexpressed (p≤0.02). Importantly, higher transcript levels of disc large (drosophila) homolog-associated protein 5 (DLGAP5)/discs large homolog 7 (DLG7)/hepatoma up-regulated protein (HURP), hyaluronan-mediated motility receptor (HMMR) and cyclin B1 (CCNB1) were associated with higher Gleason score and more advanced systemic progression. Since the products of HMMR and CCNB1 have been identified recently as molecular markers of CaP progression, we postulated that DLG7 has prognostic value too. To test this hypothesis, we measured transcript levels for DLG7 in a 150-pair case-control cohort. The cases (progression to systemic disease within six years of surgery) and controls (no progression within eight years) were matched for clinical and pathologic prognostic variables, including grade, stage, and preoperative serum levels of PSA. The overall prognostic ability of DLG7, as tested in receiver operating characteristic analysis was of 0.74 (95% CI, 0.68 to 0.8). Overall, our data indicate that expression of DLG7, a hypoxia-controlled gene, holds prognostic potential in high-risk CaP; this also demonstrates that variation of oxygen tension may constitute a tool for identification of novel biomarkers for CaP.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…HER3 and HER4 quantifications were previously determined by same method by amplifying a 365 and 265 bp fragment, respectively (Memon et al, 2004). Beta-actin mRNA was used as an endogenous RNA control, which has been used as control gene in various studies on bladder cancer (Vageli et al, 1996;Chiu et al, 2002) as well as on breast cancer (Agudo et al, 2004). Specificity was verified by the size of the PCR product on agarose gel electrophoresis and nucleotide sequencing using a 310 genetic analyser (Applied Biosystems).…”

Section: Preparation Of Total Rnamentioning

confidence: 99%

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

et al. 2006

View full text Add to dashboard Cite

Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder cancer, where the survival was followed for a median of 38.5 months (range 1 -117 months). Expression of HER1 and HER2 alone showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4 correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4 (P ¼ 0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3 and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P ¼ 0.0005). Our results suggest that the final outcome of patients with high HER1-and HER2-expressing tumours depends on the expression of HER3 and HER4.

show abstract

“…We therefore quantified transcripts of beta-actin as an endogenous RNA control, and each sample was normalised on the basis of its beta-actin mRNA contents. Beta-actin has been used as control gene in various studies on bladder cancer (Vageli et al, 1996;Chiu et al, 2002) as well as in breast cancer (Agudo et al, 2004). All the quantifications in this study are presented as the ratio between the target gene and beta-actin.…”

Section: Real-time Rt -Pcr Quantification Of Mrnamentioning

confidence: 99%

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

et al. 2004

View full text Add to dashboard Cite

The epidermal growth factor system has been associated to prognosis in patients with bladder cancer based mainly on the expression of the epidermal growth factor (EGF) receptor 1 (EGFR) and HER2 and their activating ligands. Since limited information exists concerning the expression of other parts of the EGF system, we examined the expression of the receptors HER3 and HER4 and their activating ligands, the heregulins (HRGs), in bladder cancer patients. Biopsies from bladder cancer tumours were obtained from 88 patients followed for a median of 23 months (range, 1 -97 months). The mRNA content of four ligands and their isoforms (HRG1a, HRG1b, HRG2a, HRG2b, HRG3 and HRG4) and two receptors (HER3 and HER4) was quantified by real-time PCR. A significantly lower mRNA expression level of HER3 (P ¼ 0.0003), HRG2a (P ¼ 0.0159), HRG2b (P ¼ 0.0007) and HRG4 (Po0.0001) was observed in muscle-invasive (T2 -T4) tumours as compared to superficial (Ta) tumours. The expression of HER3 mRNA correlated strongly to overall survival (P ¼ 0.0042); increased expression of HER4 (P ¼ 0.0261) and HRG4 (P ¼ 0.0245) was also associated with better prognosis. Interestingly, patients with coexpression of HER3 (P ¼ 0.0034) or HER4 (P ¼ 0.0080) together with their stimulating ligand HRG4 showed even better survival than for HER3 or HER4 alone. Our results together with previous data suggest a dual face for the EGF system. While it is well established that an increased signalling through HER1 and HER2 is related to a poor prognosis, our data suggest that signalling through HER3 and HER4 is related to a favourable outcome in bladder cancer patients.

show abstract

Potential molecular marker for detecting transitional cell carcinoma

Cited by 33 publications

References 14 publications

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

Contact Info

Product

Resources

About